Serial Number | 97777777 |
Word Mark | HAEBREYK |
Filing Date | Thursday, February 2, 2023 |
Status | 686 - PUBLISHED FOR OPPOSITION |
Status Date | Tuesday, September 10, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, September 10, 2024 |
Goods and Services | Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, February 9, 2023 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | CSL Behring GmbH |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | Marburg D-35041 DE |
Party Name | CSL Behring GmbH |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | Marburg D-35041 DE |
Event Date | Event Description |
Tuesday, February 7, 2023 | NEW APPLICATION ENTERED |
Wednesday, November 1, 2023 | ASSIGNED TO EXAMINER |
Monday, February 5, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Thursday, February 9, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Tuesday, November 7, 2023 | NON-FINAL ACTION WRITTEN |
Tuesday, November 7, 2023 | NON-FINAL ACTION E-MAILED |
Tuesday, November 7, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Wednesday, July 24, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Wednesday, July 24, 2024 | ASSIGNED TO LIE |
Wednesday, July 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, August 5, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, August 21, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, September 10, 2024 | PUBLISHED FOR OPPOSITION |
Tuesday, September 10, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |